

KMS KMS MEDISURGI LIMITED

CIN L51397MH1999PLC119118

Plot No-297/301 May Building, Gr. Floor Marine lines (EAST), Princess Street, Mumbai City
MH 400002 IN Ph-022-66107700/22,022-67498822, Facsimile: +91-22-22061111,
Website: -www.kmsgroup.in, E-mail Id:- info@kmsgroup.in

To,
Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai-400001

Subject: Outcome of the Board Meeting of the Company
Ref: KMS Medisurgi Limited (Scrip Code- 540468)

Dear Sir,

Please find enclosed herewith **Unaudited Financial Results** for the half year period ended **30th September, 2019** along with **Limited Review Report** approved by the Board of Directors of the Company at its meeting held today i.e. **14th November, 2019** in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Meeting of Board of Directors of the Company **commenced at 05:00 p.m. and concluded at 07.15 p.m.**

This is for your information and records.

Thanking You

FOR, KMS MEDISURGI LIMITED

FOR KMS MEDISURGI LIMITED


MANAGING DIRECTOR

Gaurang Prataprai Kanakia
Managing Director
DIN: 00346180

Date: 14th November, 2019
Place: Mumbai



KALPESH JAIN AND ASSOCIATES

CHARTERED ACCOUNTANTS

204, Shamaldas Gandhi Marg., Room No. 5d, Prabhat Co-op. Soc. Ltd.,

Princess Street, Next to Geeta Bhavan Hotel, Mumbai - 400 002.

Tel. No. 022 22090367, + 91 9820559914 | Email Id :-kjainassociates@gmail.com

LIMITED REVIEW REPORT

To
The Board of Directors of
KMS MEDISURGI LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMS Medisurgi Limited** for the quarter ended 30th September 2019 (“the statement”) being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement which is the responsibility of the Company’s Management and has been approved by the Board of Directors has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. . Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No CIR/CFD/FAC/62/2016 dated 5 July 2016 including manner in which it is to be disclosed, or that it contains any material misstatement.

For **Kalpesh Jain & Associates.**
Chartered Accountants
Firm's Registration No : 132603W



A handwritten signature in black ink that reads "Kalpesh" with a stylized flourish.

Kalpesh Jain
Partner
M. No. 140164
UDIN : 19140164AAAACG9977


Place : Mumbai
Date : 14th November 2019

KMS MEDISURGI LTD**BALANCE SHEET AS AT 30th SEPTEMBER 2019**

	Notes	Sep-19	Sep-19	Mar-19
EQUITY AND LIABILITIES				
SHAREHOLDERS FUNDS :				
Share Capital	2	3,30,00,000		3,30,00,000
Reserves & Surplus	3	<u>3,00,76,073</u>		<u>2,95,47,413</u>
			6,30,76,073	<u>6,25,47,413</u>
NON CURRENT LIABILITIES				
Long Term Borrowings	4		1,09,21,561	1,12,76,399
CURRENT LIABILITIES				
1) Short Term Borrowings	5	-		-
2) Trade Payables	6	2,32,13,103		2,94,80,301
3) Other Current Liabilities	7	13,48,349		7,54,479
4) Short Term Provisions	8	<u>13,12,624</u>		<u>13,12,624</u>
			2,58,74,076	<u>3,15,47,404</u>
			<u>9,98,71,710</u>	<u>10,53,71,216</u>
ASSETS				
NON CURRENT ASSETS				
<u>Fixed Assets</u>				
Tangible Assets	9		2,01,20,591	2,20,35,035
Non Current Investments	10		16,012	16,012
Long Term Loans & Advances	11		-	-
CURRENT ASSETS				
1) Inventories	12	85,55,153		1,80,99,802
2) Trade Receivables	13	5,94,59,243		5,05,07,691
3) Cash & Cash Equivalents	14	62,36,461		1,17,52,881
4) Short Term Loans & Advances	15	54,19,878		28,95,423
5) Other Current Assets	16	<u>64,372</u>		<u>64,372</u>
			7,97,35,107	<u>8,33,20,169</u>
			<u>9,98,71,710</u>	<u>10,53,71,216</u>

FOR KMS MEDISURGI LIMITED


MANAGING DIRECTOR

KMS MEDISURGI LIMITED

DIRECTOR

KMS MEDISURGI LIMITED

Registered office : 297/301 May Building, Gr. Floor Marine lines(East) Princess Street Mumbai 400002.

Tel No.:- (022) 66107700 E-mail: info@kmsgroup.in

CIN: L51397MH1999PLC119118, Website: www.kmsgroup.in

Statement Standalone financial result for the Half Year Ended 30th September, 2019

(Rs. In Lakhs)

	Particulars	Half year ended on			Year ended 31st March	
		30-09-2019	31-03-2019	30-09-2018	2019	2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	Income from operations					
	a. Net Sales/Income from Operations	513.923	524.51	461.500	986.01	732.36
	b. Other Operating Income	-	-	-	-	-
	Total income from operations (net)	513.923	524.51	461.50	986.01	732.36
2	Expenditure					
	a. Cost of materials consumed & Director Exp.	358.798	403.63	337.90	741.53	531.21
	b. Purchases of stock-in-trade	-	63.97	16.20	80.17	49.58
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	44.540	(44.56)	25.10	(19.46)	(25.08)
	d. Employee Cost	29.172	58.55	23.90	82.45	52.95
	e. Depreciation	20.034	24.39	18.30	42.69	45.19
	f. Other expenditure	52.615	42.42	28.20	70.62	76.61
	Total expenses	505.159	548.40	449.60	998.00	730.46
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	8.764	(23.89)	11.90	(11.99)	1.90
4	Other Income	0.015	39.30	2.80	42.10	35.32
5	Profit before Interest and Exceptional Items (3+4)	8.779	15.41	14.70	30.11	37.22
6	Finance costs	2.193	5.90	3.20	9.10	19.14
7	Profit after Interest but before Exceptional Items (5-6)	6.586	9.51	11.50	21.01	18.08
8	Exceptional Items	-	-	-	-	-
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	6.586	9.51	11.50	21.01	18.08
10	Tax expense	-	8.37	-	8.37	8.50
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	6.586	1.14	11.50	12.64	9.58
12	Extraordinary Item	-	-	-	-	-
13	Net Profit(+)/ Loss(-) for the period (11-12)	6.586	1.14	11.50	12.64	9.58
14	Share of profit / (loss) of associates *	-	-	-	-	-
15	Minority interest *	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	-	-	-	-	-
17	Paid-up equity share capital (Face Value of Rs. 10 Each)	330	330	330	330	330
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	300.761	295	295	295	285
19	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.16	0.03	0.26	0.37	0.29
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.16	0.03	0.26	0.37	0.29

* Applicable in the case of consolidated results.

Note:

- The above results, reviewed and recommended by the Audit Committee were approved and taken on record by the board of Directors of the company at its
- Segment reporting as defined in Accounting Standards is not applicable, as the business of the company falls in one segment.
- Corresponding figures of the previous period/year have been regrouped/restated, wherever necessary.
- The Company is listed on SME platform of BSE and the provision of IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules,2015,
- The above figures have been regrouped or rearranged where ever considered necessary.

For and on behalf of Board of Directors of
KMS MEDISURGI LIMITED
FOR KMS MEDISURGI LIMITED

MANAGING DIRECTOR

Managing Director

KMS MEDISURGI LIMITED

Rohit

DIRECTOR

Director

Place : Mumbai

Date : 14-11-2019

KMS MEDISURGI PRIVATE LTD
Cash Flow Statement for the year ended 30th September 2019

	30/09/2019	31/03/2019
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Exceptional Items	5,28,660	12,32,247
Adjustments for :		
Depreciation	20,03,427	42,68,902
Interest paid	96,471	1,22,198
Interest received	(1,547)	(7,41,771)
(Profit) / Loss on sales of Investment	-	-
(Profit) / Loss on sales of fixed assets (net)	-	-
	20,98,351	36,49,329
Operating Profit before Working Capital Changes	26,27,011	48,81,576
Adjustments for :		
Increase / (Decrease) in Trade payables	(62,67,198)	89,62,767
Increase / (Decrease) in Other Current Liabilities	5,93,870	3,11,107
Increase / (Decrease) in Short Term Provisions	-	8,28,850
(Increase) / Decrease in Inventories	95,44,649	(51,11,399)
(Increase) / Decrease in Other Current Assets	-	(64,372)
(Increase) / Decrease in Short Term Loans & Advances	(23,65,555)	14,32,194
(Increase) / Decrease in Trade & Other receivables	(89,51,552)	(36,81,166)
Cash Generated from Operations	(48,18,775)	75,59,557
Direct taxes paid	(1,58,900)	(27,204)
Net Cash from Operating Activities	[A] (49,77,675)	75,32,353
B CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Assets	(88,983)	(38,52,500)
Sales of Assets	-	-
Sales / (Purchases) of Investments	-	-
Interest received	1,547	7,41,771
Dividend received	-	-
Net Cash from Investing Activities	[B] (87,436)	(31,10,729)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from borrowings	(3,54,838)	32,18,045
Repayment of borrowings	-	(1,09,93,173)
Increase in Share Capital	-	-
Increase in Share Premium	-	-
Interest Expenses	(96,471)	(1,22,198)
Dividend On Equity Shares	-	(1,65,000)
Dividend Distribution Tax	-	(33,590)
Net Cash Flow from Financial Activities	[C] (4,51,309)	(80,95,916)
Net Cash increase/(Decrease) in cash and Cash equivalents	(A+B+C) (55,16,420)	(36,74,292)
Cash and Cash Equivalents (Opening) :		
Cash on Hand	4,42,802	4,56,021
Balance with Banks	1,13,10,079	1,49,71,152
	1,17,52,881	1,54,27,173
Cash and Cash Equivalents (Closing) :		
Cash on Hand	6,79,397	4,42,802
Balance with Banks	55,57,064	1,13,10,079
	62,36,461	1,17,52,881

FOR KMS MEDISURGI LIMITED


MANAGING DIRECTOR

KMS MEDISURGI LIMITED


DIRECTOR